| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | 10%+ Owner | C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVE, GEORGE TOWN, CAYMAN ISLANDS | Deep Track Biotechology Master Fund, Ltd. /s/ David Kroin, Director | 10 Feb 2026 | 0002015536 |
| Deep Track Special Opportunities Fund, LP | 10%+ Owner | 200 GREENWICH AVENUE, 3RD FLOOR, GREENWICH | Deep Track Special Opportunities Fund, LP, By David Kroin, Managing Member of the Investment Manager | 10 Feb 2026 | 0002077950 |
| Deep Track Capital, LP | 10%+ Owner | 200 GREENWICH AVENUE, 3RD FLOOR, GREENWICH | Deep Track Capital, LP /s/ David Kroin, Managing Member of the General Partner of the Investment Adviser | 10 Feb 2026 | 0001856083 |
| KROIN DAVID | 10%+ Owner | C/O DEEP TRACK CAPITAL, LP, 200 GREENWICH AVENUE, 3RD FLOOR, GREENWICH | /s/ David Kroin | 10 Feb 2026 | 0001397513 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LBRX | Pre-Funded Warrants (Right to Buy) | Purchase | $8,011,622 | +378,444 | $21.17 | 378,444 | 06 Feb 2026 | Common Stock | 378,444 | $0.000100 | Direct | F1, F2, F3 | |
| transaction | LBRX | Pre-Funded Warrants (Right to Buy) | Purchase | $1,988,383 | +93,925 | $21.17 | 93,925 | 06 Feb 2026 | Common Stock | 93,925 | $0.000100 | By Deep Track Special Opportunities Fund, LP | F1, F2, F4 |
| Id | Content |
|---|---|
| F1 | The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire. |
| F2 | Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the "Maximum Percentage"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock. |
| F3 | Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests. |
| F4 | Represents securities held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests. |